Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor

DJ MacEwan, GD Kim and G Milligan

Division of Biochemistry and Molecular Biology, University of Glasgow, Scotland, UK.

Many agonist ligands are known experimentally to display a range of efficacies and potencies in different tissues and preparations. To analyze the role of the levels of receptor expression and availability in the intrinsic activities and potencies of agonists, the function of a number of beta-adrenoceptor ligands was examined in clones of neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor, as well as after treatment of these cell lines with the irreversible beta-adrenoceptor antagonist bromoacetyl alprenolol menthane (BAAM). Clone beta N22 expressed approximately 10-fold higher levels of the receptor than did clone beta N17. In measurements of agonist stimulation of adenylyl cyclase activity in membranes of these cells or agonist stimulation of the formation of the complex of Gs alpha and adenylyl cyclase, which acts as the high affinity binding site for [3H]forskolin in whole cells, a series of beta-adrenoceptor agonists, including dichloroisoprenaline, ephedrine, dobutamine, and salbutamol, displayed higher intrinsic activity and showed concentration-response curves that were substantially to the left (lower EC50 values) in clone beta N22, compared with clone beta N17. Treatment of clone beta N22 cells with varying concentrations of BAAM reduced the intrinsic activity of these ligands and shifted the concentration-response curves for these agents to the right. In clone beta N22 cells and membranes, reduction in the observed intrinsic activity for ephedrine required elimination of a smaller fraction of the beta 2-adrenoceptor reserve than for salbutamol and reduction in the effect of the full agonists isoprenaline and epinephrine was noted only with high fractional elimination of the receptor pool. The effect of isoprenaline was substantially reduced, however, by BAAM treatment of clone beta N17 cells, where the beta 2- adrenoceptor number approached extremely low levels. Analysis of the data using the formalisms of Whaley et al. [Mol. Pharmacol. 45:481-489 (1994)] showed that prediction of alterations in agonist potency with receptor number for full agonists can be adequately extended to partial agonists.

Volume 48, Issue 2, pp. 316-325, 08/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. J. Clark, C. A. Furman, T. D. Gilson, and J. R. Traynor Comparison of the Relative Efficacy and Potency of {micro}-Opioid Agonists to Activate G{alpha}i/o Proteins Containing a Pertussis Toxin-Insensitive Mutation J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 858 - 864. [Abstract] [Full Text] [PDF]

				J. Guo and S. R. Ikeda Endocannabinoids Modulate N-Type Calcium Channels and G-Protein-Coupled Inwardly Rectifying Potassium Channels via CB1 Cannabinoid Receptors Heterologously Expressed in Mammalian Neurons Mol. Pharmacol., March 1, 2004; 65(3): 665 - 674. [Abstract] [Full Text] [PDF]

				J. G. Baker, I. P. Hall, and S. J. Hill Influence of Agonist Efficacy and Receptor Phosphorylation on Antagonist Affinity Measurements: Differences between Second Messenger and Reporter Gene Responses Mol. Pharmacol., September 1, 2003; 64(3): 679 - 688. [Abstract] [Full Text] [PDF]

				S. Hilairet, M. Bouaboula, D. Carriere, G. Le Fur, and P. Casellas Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor: EVIDENCE FOR CROSS-TALK BLOCKED BY THE SPECIFIC CB1 ANTAGONIST, SR141716 J. Biol. Chem., June 20, 2003; 278(26): 23731 - 23737. [Abstract] [Full Text] [PDF]

				A. J. McLean, N. Bevan, S. Rees, and G. Milligan Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant beta 2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins Mol. Pharmacol., December 1, 1999; 56(6): 1182 - 1191. [Abstract] [Full Text]

				C. K. Billington, I. P. Hall, S. J. Mundell, J.-L. Parent, R. A. Panettieri Jr., J. L. Benovic, and R. B. Penn Inflammatory and Contractile Agents Sensitize Specific Adenylyl Cyclase Isoforms in Human Airway Smooth Muscle Am. J. Respir. Cell Mol. Biol., November 1, 1999; 21(5): 597 - 606. [Abstract] [Full Text]

				V. N. Jackson, D. S. Bahia, and G. Milligan Modulation of Relative Intrinsic Activity of Agonists at the Alpha-2A Adrenoceptor by Mutation of Residue 351 of G Protein Gi1alpha Mol. Pharmacol., February 1, 1999; 55(2): 195 - 201. [Abstract] [Full Text]

				D. E. Selley, Q. Liu, and S. R. Childers Signal Transduction Correlates of Mu Opioid Agonist Intrinsic Efficacy: Receptor-Stimulated [35S]GTPgamma S Binding in mMOR-CHO Cells and Rat Thalamus J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 496 - 505. [Abstract] [Full Text]

				T. Tsuda, T. Kusui, W. Hou, R. V. Benya, M. A. Akeson, G. S. Kroog, J. F. Battey, and R. T. Jensen Effect of Gastrin-Releasing Peptide Receptor Number on Receptor Affinity, Coupling, Degradation, and Modulation Mol. Pharmacol., May 1, 1997; 51(5): 721 - 732. [Abstract] [Full Text]

				G. Pozvek, J. M. Hilton, M. Quiza, S. Houssami, and P. M. Sexton Structure/Function Relationships of Calcitonin Analogues as Agonists, Antagonists, or Inverse Agonists in a Constitutively Activated Receptor Cell System Mol. Pharmacol., April 1, 1997; 51(4): 658 - 665. [Abstract] [Full Text]

				M. E. Olah and M. E. Olah Identification of A2a Adenosine Receptor Domains Involved in Selective Coupling to GS. ANALYSIS OF CHIMERIC A1/A2a ADENOSINE RECEPTORS J. Biol. Chem., January 3, 1997; 272(1): 337 - 344. [Abstract] [Full Text] [PDF]

				G. B. Whitaker, B. J. Limberg, and J. S. Rosenbaum Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121 J. Biol. Chem., June 29, 2001; 276(27): 25520 - 25531. [Abstract] [Full Text] [PDF]